Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. CROI 2019, abstract 139.
Behandeling van anale HSIL verlaagt risico anuscarcinoom
aug 2022 | HIV, Maag-darm-leveroncologie, Virale infecties